Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
62.3M
-
Number of holders
-
68
-
Total 13F shares, excl. options
-
45.9M
-
Shares change
-
-6.6M
-
Total reported value, excl. options
-
$27.6M
-
Value change
-
-$42.3M
-
Put/Call ratio
-
39.42
-
Number of buys
-
36
-
Number of sells
-
-45
-
Price
-
$0.60
Significant Holders of Elevation Oncology, Inc. - Common stock, par value $0.0001 per share (ELEV) as of Q3 2024
97 filings reported holding ELEV - Elevation Oncology, Inc. - Common stock, par value $0.0001 per share as of Q3 2024.
Elevation Oncology, Inc. - Common stock, par value $0.0001 per share (ELEV) has 68 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 45.9M shares
of 62.3M outstanding shares and own 73.69% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (5.99M shares), TANG CAPITAL MANAGEMENT LLC (4.76M shares), GOLDMAN SACHS GROUP INC (3.99M shares), FARALLON CAPITAL MANAGEMENT LLC (3.53M shares), VANGUARD GROUP INC (3.07M shares), BVF INC/IL (2.97M shares), BlackRock, Inc. (2.91M shares), Aisling Capital Management LP (2.83M shares), RENAISSANCE TECHNOLOGIES LLC (1.79M shares), and Hudson Bay Capital Management LP (1.36M shares).
This table shows the top 68 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.